MEDICUS PHARMA LTD (MDCX) Fundamental Analysis & Valuation

NASDAQ:MDCX • CA58471K2020

0.3873 USD
-0.29 (-42.87%)
At close: Mar 6, 2026
0.38 USD
-0.01 (-1.88%)
After Hours: 3/6/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MDCX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall MDCX gets a fundamental rating of 2 out of 10. We evaluated MDCX against 520 industry peers in the Biotechnology industry. MDCX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MDCX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. MDCX Profitability Analysis

1.1 Basic Checks

  • In the past year MDCX has reported negative net income.
  • MDCX had negative earnings in each of the past 5 years.
  • In the past 5 years MDCX always reported negative operating cash flow.
MDCX Yearly Net Income VS EBIT VS OCF VS FCFMDCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • With a Return On Assets value of -197.17%, MDCX is not doing good in the industry: 87.88% of the companies in the same industry are doing better.
  • With a Return On Equity value of -519.44%, MDCX is not doing good in the industry: 76.15% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -197.17%
ROE -519.44%
ROIC N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDCX Yearly ROA, ROE, ROICMDCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

1.3 Margins

  • MDCX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDCX Yearly Profit, Operating, Gross MarginsMDCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MDCX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, MDCX has more shares outstanding
  • MDCX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for MDCX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MDCX Yearly Shares OutstandingMDCX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MDCX Yearly Total Debt VS Total AssetsMDCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

  • MDCX has an Altman-Z score of -11.65. This is a bad value and indicates that MDCX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -11.65, MDCX is not doing good in the industry: 75.77% of the companies in the same industry are doing better.
  • There is no outstanding debt for MDCX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.65
ROIC/WACCN/A
WACCN/A
MDCX Yearly LT Debt VS Equity VS FCFMDCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

2.3 Liquidity

  • A Current Ratio of 1.53 indicates that MDCX should not have too much problems paying its short term obligations.
  • MDCX has a worse Current ratio (1.53) than 81.54% of its industry peers.
  • A Quick Ratio of 1.53 indicates that MDCX should not have too much problems paying its short term obligations.
  • MDCX has a Quick ratio of 1.53. This is in the lower half of the industry: MDCX underperforms 79.81% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.53
MDCX Yearly Current Assets VS Current LiabilitesMDCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MDCX Growth Analysis

3.1 Past

  • MDCX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.89%, which is quite impressive.
EPS 1Y (TTM)27.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MDCX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.48% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.14%
EPS Next 2Y21.24%
EPS Next 3Y16.13%
EPS Next 5Y20.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDCX Yearly Revenue VS EstimatesMDCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M
MDCX Yearly EPS VS EstimatesMDCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. MDCX Valuation Analysis

4.1 Price/Earnings Ratio

  • MDCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDCX Price Earnings VS Forward Price EarningsMDCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDCX Per share dataMDCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • MDCX's earnings are expected to grow with 16.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.24%
EPS Next 3Y16.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDCX Dividend Analysis

5.1 Amount

  • MDCX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDCX Fundamentals: All Metrics, Ratios and Statistics

MEDICUS PHARMA LTD

NASDAQ:MDCX (3/6/2026, 8:00:00 PM)

After market: 0.38 -0.01 (-1.88%)

0.3873

-0.29 (-42.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-23
Inst Owners9.64%
Inst Owner ChangeN/A
Ins Owners11.16%
Ins Owner Change0%
Market Cap9.73M
Revenue(TTM)N/A
Net Income(TTM)-11.16M
Analysts82.22
Price Target20.06 (5079.45%)
Short Float %5.85%
Short Ratio2.69
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-90.08%
Min EPS beat(2)-119.74%
Max EPS beat(2)-60.43%
EPS beat(4)1
Avg EPS beat(4)-54.37%
Min EPS beat(4)-119.74%
Max EPS beat(4)39.15%
EPS beat(8)2
Avg EPS beat(8)-66.95%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)37.42%
EPS NY rev (1m)-1.33%
EPS NY rev (3m)-40.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.53
P/tB 4.53
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-1.06
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -197.17%
ROE -519.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.53
Altman-Z -11.65
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.17%
EPS Next Y3.14%
EPS Next 2Y21.24%
EPS Next 3Y16.13%
EPS Next 5Y20.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-320.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.43%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICUS PHARMA LTD / MDCX FAQ

Can you provide the ChartMill fundamental rating for MEDICUS PHARMA LTD?

ChartMill assigns a fundamental rating of 2 / 10 to MDCX.


What is the valuation status for MDCX stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDICUS PHARMA LTD (MDCX). This can be considered as Overvalued.


What is the profitability of MDCX stock?

MEDICUS PHARMA LTD (MDCX) has a profitability rating of 0 / 10.


Can you provide the financial health for MDCX stock?

The financial health rating of MEDICUS PHARMA LTD (MDCX) is 5 / 10.


What is the earnings growth outlook for MEDICUS PHARMA LTD?

The Earnings per Share (EPS) of MEDICUS PHARMA LTD (MDCX) is expected to grow by 3.14% in the next year.